Related Experiment Video
Updated: Apr 13, 2026
Lung microRNA Profiling Across the Estrous Cycle in Ozone-exposed Mice
Published on: January 7, 2019
Molecular and System-Level Characterization of MMP12 Suppression in Lung Cancer: A Combined Bioinformatics and
Shriefa Almutairi1, Rima Hajjo2,3, Dima A Sabbah2
1Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman 11942, Jordan.
Abstract:
Lung cancer remains a major cause of cancer-related death, highlighting the need for new molecular targets and novel therapeutics. Matrix metalloproteinases are key regulators of invasion and microenvironment remodeling, and among them, matrix metalloproteinase-12 (MMP12) is a particularly attractive candidate whose network-level effects in cancer are still poorly defined. Herein, we applied an integrative strategy that combines bioinformatics methods with experimental validation in non-small cell lung cancer (NSCLC) cells. Protein-protein interaction (PPI) and pathway analyses of MMP12-regulated genes identified 113 downstream targets enriched in the extracellular matrix, PI3K-AKT, and immune pathways, from which an eight-gene panel (MMP12, CD44, ADAM9, NFKBIA, PSME3, SPARCL1, CCL15, and APOA1) was prioritized as a biomarker signature. Guided by these predictions, we screened a 31-compound MMP12 inhibitor library and selected five leads (C1, C7, C9, C10, and C15) for testing in H1299 cells, with C9 showing the strongest antiproliferative activity. These compounds showed antimigratory activity (C1 achieving a 90% inhibition of wound closure at its IC50 concentration), reduced clonogenic growth, cell cycle perturbation, and induction of apoptosis. Gene- and protein-expression analyses confirmed MMP12 suppression and modulation of the eight-gene panel. Upstream regulator predictions implicated reduced AKT signaling alongside an ADAM9-centered adaptive axis. Collectively, these findings highlight C1, C7, C9, C10, and C15 as promising MMP12 inhibitors, supporting their further development in preclinical lung cancer and nominating the eight-gene panel as a pharmacodynamic signature for MMP12-targeted therapies.
Insights
Researchers identified a new eight-gene biomarker panel for non-small cell lung cancer (NSCLC) and tested five matrix metalloproteinase-12 (MMP12) inhibitors, with C9 showing strong antiproliferative effects. These MMP12 inhibitors offer potential new therapies for lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- Lung cancer necessitates novel molecular targets and therapeutics due to its high mortality.
- Matrix metalloproteinase-12 (MMP12) plays a role in cancer invasion and remodeling, but its network effects are not fully understood.
- Non-small cell lung cancer (NSCLC) presents a significant clinical challenge requiring advanced treatment strategies.
Purpose of the Study:
- To define the network-level effects of MMP12 in non-small cell lung cancer (NSCLC).
- To identify a potential biomarker signature for MMP12-targeted therapies.
- To screen and validate MMP12 inhibitors for preclinical lung cancer treatment.
Main Methods:
- Integrative strategy combining bioinformatics analysis (PPI, pathway analysis) with experimental validation in NSCLC cells.
- Prioritization of an eight-gene panel (MMP12, CD44, ADAM9, NFKBIA, PSME3, SPARCL1, CCL15, APOA1) as a biomarker signature.
- Screening of a 31-compound MMP12 inhibitor library and subsequent testing of lead compounds (C1, C7, C9, C10, C15) in H1299 cells.
Main Results:
- Identified 113 downstream MMP12 targets enriched in extracellular matrix, PI3K-AKT, and immune pathways.
- Selected five lead MMP12 inhibitors (C1, C7, C9, C10, C15), with C9 demonstrating the highest antiproliferative activity.
- Validated compounds' antimigratory, anti-clonogenic, cell cycle perturbing, and apoptosis-inducing effects, confirming MMP12 suppression and biomarker modulation.
Conclusions:
- The identified eight-gene panel serves as a pharmacodynamic signature for MMP12-targeted therapies in NSCLC.
- Compounds C1, C7, C9, C10, and C15 are promising MMP12 inhibitors warranting further preclinical development for lung cancer.
- Findings highlight the therapeutic potential of targeting MMP12 and associated pathways in NSCLC treatment.
